Several recent studies demonstrating the potential of anti-CD73 antibodies in immunomodulation and cancer treatment, also show that specific anti-CD73 antibodies trigger CD73 to internalize (Terp et al., 2013), to shed from the membrane (this study, Airas et al., 2000; Geoghegan et al., 2016) or to remain intact (Airas et al., 1997; Sadej et al., 2006; Sadej and Skladanowski, 2012; Terp et al., 2013; Geoghegan et al., 2016), indicating that the effect may be epitope specific. The gene discussed is NT5E; the disease is cancer.